Synchronous primary cancers of the endometrium and ovary

Abstract

Simultaneous detection of malignancy in the endometrium and ovary represents an uncommon event. The objective of the study was to clarify the possible factors that influenced on the survival. From 1977 to 2005, totally 27 patients fulfilled the criteria and were included in the study. The medical records and the pathologic reports were reviewed. The histologic determination was followed by the World Health Organization Committee classification, and cancer stage was based on the staging system of the FIGO. The KaplanMeier survival analyses were generated and compared by the log-rank test. The incidence of synchronous primary endometrial and ovarian cancers was 3.3% in patients with endometrial cancer and 2.7% in patients with ovarian cancer. The mean survival in the group of similar histology (n ¼ 15) was 63 months, and 48 months in the group of dissimilar histology (n ¼ 12) (P ¼ 0.63). The mean survival in the group of early stage (n ¼ 21) was 68 months and 15 months in the group of advanced stage (n ¼ 6) with statistic significance (P ¼ 0.0003). However, the impact of adjuvant therapy on survival did not reach statistic significance (P ¼ 0.15 for chemotherapy; P ¼ 0.69 for radiotherapy). We conclude that the majority of the patients belonged to concordant endometrioid histology in endometrium and ovary, and it tends to be early stage and low grade with favorable prognosis. The stage had more significant influence on the survival than the histology. Adjuvant therapy should be given especially in patients with advanced stage although the optimal management remained to be determined.

Does synchronous endometrioid endometrial cancer have any prognostic effect on Stage I endometrioid ovarian cancer?

“…The median follow-up period (95 months) was sufficient to examine disease-free survival. Many studies have postulated that the survival rate of patients with SEOC is better than that of patients with EOC [4,17,18]. However, this study does not support this finding; following adjustment for histological type and stage, the prognosis was not remarkably different between SEOC and EOC in the early stages.…”

Clinicopathological characteristics of patients with synchronous primary endometrial and ovarian cancers: A review of 43 cases

“…The scope of general surgery included hysterectomy, bilateral salpingo-oophorectomy, omentectomy and appendectomy. Pelvic lymph node dissection depended on the pathological findings (9,10). The treatment of patients with ovarian cancer is generally based on chemotherapy with paclitaxel plus cisplatin (TP) regimen or cisplatin + doxorubicin + cyclophosphamide (PAC) regimen and the length of treatment ranges from 2 to 10 cycles, generally 3 to 6 cycles; however, patients with stage Ⅰ or II grade 1 ovarian cancer do not require chemotherapy.…”

Synchronous Primary Ovarian Mucinous Carcinoma and Endometrioid Endometrial Carcinoma : A rare case report.

“…In a study done by Y Chiang et al done on 23 cases of synchronous ovarian and endometrial tumours 63% showed similar histology [5] . A 10 year study done by Young Kuei Lim et al on 75 patients with synchronous tumours showed 73.9% being endometrioid endometrial cancers and 26.1 % with tumours of different histological type [6] .…”